Edison

A dedicated group of physicians, researchers, foundations, executives and parents of children with mitochondrial disease founded Edison in 2005. This group understood that breakthroughs occurring in university settings needed to be translated into therapeutics by a company dedicated to rare childhood diseases. Edison began operations in July of 2006 with a clear mandate– expedite the translation of drugs with promising therapeutic potential into clinical development for inherited mitochondrial diseases. Two years later Edison’s first drug candidate EPI-A0001 is entering Phase 1 trials, and several promising candidates are in the pipeline. Edison is now leveraging its expertise in the mitochondria to tackle Huntington’s Disease and other conditions involving mitochondrial dysfunction, as well as defects in the generation and regulation of energy metabolism.